A new study reports that a protein previously identified as a possible therapeutic target in esophageal cancer, CXCR4, may be a related method for treating these patients.
According to this study’s results, researchers state that CXCR4 doesn’t appear to be a promising therapeutic alternative for patients with innovative, inoperable or chemotherapy-resistant pleural mesothelioma.
The analysis,”Targeting CXCR4 with [68Ga]Pentixafor: An appropriate theranostic strategy in pleural mesothelioma? ,” was printed in Oncotarget.
CXCR4 is highly generated in over 20 tumor forms, promoting tumor growth and development, tumor invasiveness, and metastasis. That’s what research from lab-grown cells have revealed. However, a publication PET/CT imaging representative discovering CXCR4 in cancer mouse models and sufferers has revealed differently.
Robust overexpression of CXCR4 was reported in human cell lines along with the vast majority of cancerous tissues, so investigators planned to utilize this imaging agent, called [68Ga]Pentixafor to inquire into the feasibility of CXCR4 as a therapeutic goal in mesothelioma sufferers.
To evaluate CXCR4 as a possible therapeutic target, its levels were quantified by PET/CT scans in six patients that never had obtained therapy. Five were men and one was female, with ages ranging from 54 to 80 years.
Following imaging, surgery was performed in most patients and samples have been collected to search for the amount and supply of this CXCR4 protein. Besides the samples available from patients undergoing imaging, nine surgical mesothelioma samples from different patients (eight men and one female) were utilized.
Info from sample and imaging investigation appears to indicate a decrease frequency of CXCR4 in cancerous cells compared to that which was reported previously. On the picture analysis of the tests, not one of those six patients presented related focal CXCR4-positive lesions. Concerning the tissue analysis of membranous CXCR4, all samples were negative to CXCR4, but no signs of intracellular CXCR4 has been discovered.
“compared to previous reports, our data indicate broadly absence of CXCR4 expression in pleural mesothelioma. Hence, strong cell surface expression ought to be confirmed before targeting this chemokine receptor for identification and/or treatment,” the investigators wrote.
CXCR4 is a protein that functions as a receptor in the membranes of cells. CXCR4 and its ligand CXCL12 play a significant role in many physiological processes that depend on the recruiting of different tissues, including stem cells, progenitor cells and immune cells.
The article Researchers Identify CXCR4 as Weak Therapeutic Target for Pleural Mesothelioma appeared initially on The Asbestos Cancer Organization.